Invention Grant
- Patent Title: Zinc-charged peptides for the treatment of cancer and alzheimer's disease
-
Application No.: US17544773Application Date: 2021-12-07
-
Publication No.: US11639372B1Publication Date: 2023-05-02
- Inventor: Men Hwei Tsai
- Applicant: Men Hwei Tsai
- Applicant Address: US CA Duarte
- Assignee: Men Hwei Tsai
- Current Assignee: Men Hwei Tsai
- Current Assignee Address: US CA Duarte
- Agency: Trojan Law Offices
- Main IPC: C07K7/06
- IPC: C07K7/06 ; C07K14/47 ; A61P25/28 ; A61K47/18 ; A61K33/30 ; A61P35/00 ; A61K38/08 ; C07K4/12

Abstract:
The present invention is generally directed to chemically synthesized peptides that are charged with zinc ions (herein “zinc-charged peptides”). The chemically synthesized peptides are based on the amino acid sequence of alpha-lactalbumin. The present invention is further directed to a method of preparing these two zinc-charged peptides by charging the chemically synthesized peptides with zinc ions. It is observed that charging these peptides with zinc ions activate the peptide's ability to induce apoptosis in cancer cell lines, as well as increase ATP, reduce Tau protein and inhibit P38 in the brain. The zinc-charged peptides are thus capable of treating cancer and diseases involving tauopathy such as Alzheimer's Disease. The present invention is thus further directed to a method of treating cancer and diseases involving tauopathy such as Alzheimer's Disease using the zinc-charged peptides.
Information query